MDS & amp; CMML: Diagnostic and classification
Bull Cancer. 2023 Jul 13:S0007-4551(23)00284-9. doi: 10.1016/j.bulcan.2023.02.030. Online ahead of print.ABSTRACTIn 2023, a diagnosis process of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) is mainly based on morphological results obtained on bone marrow and blood smears which could be completed by cytogenetical analyses. Due to recent finding, flow cytometry data are recognized as useful for the diagnosis of CMML especially. Actual classifications and prognostic scoring systems have changed and nowadays include results of high-throughput sequencing approaches in addition to cytogenetical result...
Source: Bulletin du Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Orianne Wagner-Ballon Olivier Kosmider Source Type: research
Juvenile myelomonocytic leukemia and pediatric myelodysplastic syndromes
Bull Cancer. 2023 Jul 13:S0007-4551(23)00286-2. doi: 10.1016/j.bulcan.2023.03.026. Online ahead of print.ABSTRACTJuvenile myelomonocytic leukemia (JMML) and myelodysplastic syndromes (MDS) of children are rare and aggressive diseases. They both have the particularity of being very frequently associated with an underlying predisposition syndrome, which must be systematically investigated by meticulous clinical exam completed by molecular analysis on fibroblasts, in order to guarantee the best therapeutic management. New generation sequencing techniques have made it possible to better define the landscape of constitutional p...
Source: Bulletin du Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Marion Strullu Thierry Leblanc Elodie Lainey Source Type: research
MDS & amp; CMML: Diagnostic and classification
Bull Cancer. 2023 Jul 13:S0007-4551(23)00284-9. doi: 10.1016/j.bulcan.2023.02.030. Online ahead of print.ABSTRACTIn 2023, a diagnosis process of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) is mainly based on morphological results obtained on bone marrow and blood smears which could be completed by cytogenetical analyses. Due to recent finding, flow cytometry data are recognized as useful for the diagnosis of CMML especially. Actual classifications and prognostic scoring systems have changed and nowadays include results of high-throughput sequencing approaches in addition to cytogenetical result...
Source: Bulletin du Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Orianne Wagner-Ballon Olivier Kosmider Source Type: research
Juvenile myelomonocytic leukemia and pediatric myelodysplastic syndromes
Bull Cancer. 2023 Jul 13:S0007-4551(23)00286-2. doi: 10.1016/j.bulcan.2023.03.026. Online ahead of print.ABSTRACTJuvenile myelomonocytic leukemia (JMML) and myelodysplastic syndromes (MDS) of children are rare and aggressive diseases. They both have the particularity of being very frequently associated with an underlying predisposition syndrome, which must be systematically investigated by meticulous clinical exam completed by molecular analysis on fibroblasts, in order to guarantee the best therapeutic management. New generation sequencing techniques have made it possible to better define the landscape of constitutional p...
Source: Bulletin du Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Marion Strullu Thierry Leblanc Elodie Lainey Source Type: research
MDS & amp; CMML: Diagnostic and classification
Bull Cancer. 2023 Jul 13:S0007-4551(23)00284-9. doi: 10.1016/j.bulcan.2023.02.030. Online ahead of print.ABSTRACTIn 2023, a diagnosis process of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) is mainly based on morphological results obtained on bone marrow and blood smears which could be completed by cytogenetical analyses. Due to recent finding, flow cytometry data are recognized as useful for the diagnosis of CMML especially. Actual classifications and prognostic scoring systems have changed and nowadays include results of high-throughput sequencing approaches in addition to cytogenetical result...
Source: Bulletin du Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Orianne Wagner-Ballon Olivier Kosmider Source Type: research
Juvenile myelomonocytic leukemia and pediatric myelodysplastic syndromes
Bull Cancer. 2023 Jul 13:S0007-4551(23)00286-2. doi: 10.1016/j.bulcan.2023.03.026. Online ahead of print.ABSTRACTJuvenile myelomonocytic leukemia (JMML) and myelodysplastic syndromes (MDS) of children are rare and aggressive diseases. They both have the particularity of being very frequently associated with an underlying predisposition syndrome, which must be systematically investigated by meticulous clinical exam completed by molecular analysis on fibroblasts, in order to guarantee the best therapeutic management. New generation sequencing techniques have made it possible to better define the landscape of constitutional p...
Source: Bulletin du Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Marion Strullu Thierry Leblanc Elodie Lainey Source Type: research
MDS & amp; CMML: Diagnostic and classification
Bull Cancer. 2023 Jul 13:S0007-4551(23)00284-9. doi: 10.1016/j.bulcan.2023.02.030. Online ahead of print.ABSTRACTIn 2023, a diagnosis process of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) is mainly based on morphological results obtained on bone marrow and blood smears which could be completed by cytogenetical analyses. Due to recent finding, flow cytometry data are recognized as useful for the diagnosis of CMML especially. Actual classifications and prognostic scoring systems have changed and nowadays include results of high-throughput sequencing approaches in addition to cytogenetical result...
Source: Bulletin du Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Orianne Wagner-Ballon Olivier Kosmider Source Type: research
Capmatinib in advanced NSCLC for previously treated patients with MET exon 14 skipping mutation
Bull Cancer. 2023 Jul 11:S0007-4551(23)00288-6. doi: 10.1016/j.bulcan.2023.05.005. Online ahead of print.NO ABSTRACTPMID:37442707 | DOI:10.1016/j.bulcan.2023.05.005 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - July 13, 2023 Category: Cancer & Oncology Authors: Cl émence Basse Lucie R égaldo-Saint Blancard Source Type: research
Capmatinib in advanced NSCLC for previously treated patients with MET exon 14 skipping mutation
Bull Cancer. 2023 Jul 11:S0007-4551(23)00288-6. doi: 10.1016/j.bulcan.2023.05.005. Online ahead of print.NO ABSTRACTPMID:37442707 | DOI:10.1016/j.bulcan.2023.05.005 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - July 13, 2023 Category: Cancer & Oncology Authors: Cl émence Basse Lucie R égaldo-Saint Blancard Source Type: research
Pathophysiology of myelodysplastic syndromes
Bull Cancer. 2023 Jul 7:S0007-4551(23)00281-3. doi: 10.1016/j.bulcan.2023.02.026. Online ahead of print.ABSTRACTDuring aging, the onset of mutations at low frequency in hematopoietic cells or clonal hematopoiesis of indeterminate significance favors the evolution towards hemopathies such as myelodysplastic syndromes or acute leukemias, but also cardiovascular diseases and other pathologies. Acute or chronic inflammation related to age influences the clonal evolution and the immune response. Conversely, mutated hematopoietic cells create an inflammatory bone marrow environment facilitating their expansion. Various pathophys...
Source: Bulletin du Cancer - July 9, 2023 Category: Cancer & Oncology Authors: Michaela Fontenay Ismael Boussaid Nicolas Chapuis Source Type: research
Pathophysiology of myelodysplastic syndromes
Bull Cancer. 2023 Jul 7:S0007-4551(23)00281-3. doi: 10.1016/j.bulcan.2023.02.026. Online ahead of print.ABSTRACTDuring aging, the onset of mutations at low frequency in hematopoietic cells or clonal hematopoiesis of indeterminate significance favors the evolution towards hemopathies such as myelodysplastic syndromes or acute leukemias, but also cardiovascular diseases and other pathologies. Acute or chronic inflammation related to age influences the clonal evolution and the immune response. Conversely, mutated hematopoietic cells create an inflammatory bone marrow environment facilitating their expansion. Various pathophys...
Source: Bulletin du Cancer - July 9, 2023 Category: Cancer & Oncology Authors: Michaela Fontenay Ismael Boussaid Nicolas Chapuis Source Type: research
Pathophysiology of myelodysplastic syndromes
Bull Cancer. 2023 Jul 7:S0007-4551(23)00281-3. doi: 10.1016/j.bulcan.2023.02.026. Online ahead of print.ABSTRACTDuring aging, the onset of mutations at low frequency in hematopoietic cells or clonal hematopoiesis of indeterminate significance favors the evolution towards hemopathies such as myelodysplastic syndromes or acute leukemias, but also cardiovascular diseases and other pathologies. Acute or chronic inflammation related to age influences the clonal evolution and the immune response. Conversely, mutated hematopoietic cells create an inflammatory bone marrow environment facilitating their expansion. Various pathophys...
Source: Bulletin du Cancer - July 9, 2023 Category: Cancer & Oncology Authors: Michaela Fontenay Ismael Boussaid Nicolas Chapuis Source Type: research
Pathophysiology of myelodysplastic syndromes
Bull Cancer. 2023 Jul 7:S0007-4551(23)00281-3. doi: 10.1016/j.bulcan.2023.02.026. Online ahead of print.ABSTRACTDuring aging, the onset of mutations at low frequency in hematopoietic cells or clonal hematopoiesis of indeterminate significance favors the evolution towards hemopathies such as myelodysplastic syndromes or acute leukemias, but also cardiovascular diseases and other pathologies. Acute or chronic inflammation related to age influences the clonal evolution and the immune response. Conversely, mutated hematopoietic cells create an inflammatory bone marrow environment facilitating their expansion. Various pathophys...
Source: Bulletin du Cancer - July 9, 2023 Category: Cancer & Oncology Authors: Michaela Fontenay Ismael Boussaid Nicolas Chapuis Source Type: research
Environmental and occupational risk factors for myelodysplastic syndrome
Bull Cancer. 2023 Jul 5:S0007-4551(23)00279-5. doi: 10.1016/j.bulcan.2023.02.024. Online ahead of print.ABSTRACTChemotherapy and radiotherapy for a previous cancer can lead to subsequent myelodysplastic syndrome (MDS). However, these therapy-related cases are hypothesized to explain only 5 % of diagnosed MDS cases. Environmental or occupational exposure to chemicals or radiations has also been reported to be associated with higher risk of MDS. The present review analyses those studies evaluating the association of MDS with environmental or occupational risk factors. There is sufficient evidence that environmental or occupa...
Source: Bulletin du Cancer - July 7, 2023 Category: Cancer & Oncology Authors: Robert Garnier Source Type: research
Environmental and occupational risk factors for myelodysplastic syndrome
Bull Cancer. 2023 Jul 5:S0007-4551(23)00279-5. doi: 10.1016/j.bulcan.2023.02.024. Online ahead of print.ABSTRACTChemotherapy and radiotherapy for a previous cancer can lead to subsequent myelodysplastic syndrome (MDS). However, these therapy-related cases are hypothesized to explain only 5 % of diagnosed MDS cases. Environmental or occupational exposure to chemicals or radiations has also been reported to be associated with higher risk of MDS. The present review analyses those studies evaluating the association of MDS with environmental or occupational risk factors. There is sufficient evidence that environmental or occupa...
Source: Bulletin du Cancer - July 7, 2023 Category: Cancer & Oncology Authors: Robert Garnier Source Type: research
